Scaling telehealth rehabilitation may reduce travel and facility constraints but must address device/internet availability, ...
TuHURA Biosciences, Inc. ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has ...